Please login to the form below
Atripla
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Atripla was produced by Gilead Sciences.
MSD claims EU approval for two HIV products
Merck has suggested Delstrigo is slightly more effective than Gilead’s widely-prescribed Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate), which made $1.3bn in sales last year.
Gilead gets EU nod for TAF-based triple therapy for HIV
Atripla in 20016. ... Since then, Atripla has grown into a $3bn-plus product. "People living with HIV today are increasingly likely to be receiving treatment for other conditions - such as heart and liver disease -
ViiV and Janssen take long-acting HIV regimen into phase III
Gilead currently dominates the HIV treatment sector thanks to drugs like Truvada (emtricitabine and tenofovir disoproxil fumarate) and Atripla (favirenz/emtricitabine/tenofovir disoproxil fumarate), but ViiV is fighting back.
ViiV agrees $1.5bn deal to acquire BMS' HIV assets
cobicistat), Sustiva (efavirenz) and big-selling Atripla (efavirenz, emtricitabine, and tenofovir).
ViiV boosted by positive phase III results for HIV drug Triumeq
The current HIV fixed-dose combination market leader is by Gilead's Atripla (tenofovir, emtrcitabine and efavirenz), which in 2013 achieved sales of $3.6bn.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- FDA hands BMS and bluebird bio a priority review for ide-cel
- 20 for 2020 – Five pharma companies to watch
- Using Artificial Intelligence to Transform Pharma
- Session 4: Systems Innovation Insight and Thinking
- Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease
PMHub
EPG Health
REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
